KFU. Card publication. Neutralizing Antibodies in COVID-19 Serum from Tatarstan, Russia

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

NEUTRALIZING ANTIBODIES IN COVID-19 SERUM FROM TATARSTAN, RUSSIA

Form of presentation

Articles in international journals and collections

Year of publication

2023

Язык

андийский

Authors, employees of KFU

Khamza Shaymaa , author

Bibliographic description in the original language

Hamza S, Martynova E, Garanina E, Shakirova V, Bilalova A, Moiseeva S, Khaertynova I, Ohlopkova O, Blatt N, Markelova M, Khaiboullina S. Neutralizing Antibodies in COVID-19 Serum from Tatarstan, Russia. Int J Mol Sci. 2023 Jun 15;24(12):10181. doi: 10.3390/ijms241210181. PMID: 37373331; PMCID: PMC10299584.

Annotation

MDPI

Keywords

neutralizing antibodies, COVID-19, serum, Th1 lymphocyte

The name of the journal

MDPI

URL

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299584/

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=283963&p_lang=2

Full metadata record

Field DC	Value	Language
dc.contributor.author	Khamza Shaymaa	ru_RU
dc.date.accessioned	2023-01-01T00:00:00Z	ru_RU
dc.date.available	2023-01-01T00:00:00Z	ru_RU
dc.date.issued	2023	ru_RU
dc.identifier.citation	Hamza S, Martynova E, Garanina E, Shakirova V, Bilalova A, Moiseeva S, Khaertynova I, Ohlopkova O, Blatt N, Markelova M, Khaiboullina S. Neutralizing Antibodies in COVID-19 Serum from Tatarstan, Russia. Int J Mol Sci. 2023 Jun 15;24(12):10181. doi: 10.3390/ijms241210181. PMID: 37373331; PMCID: PMC10299584.	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=283963&p_lang=2	ru_RU
dc.description.abstract	MDPI	ru_RU
dc.description.abstract	The severity of COVID-19 is a result of the complex interplay between various branches of the immune system. However, our understanding of the role of neutralizing antibodies and the activation of cellular immune response in COVID-19 pathogenesis remains limited. In this study, we investigated neutralizing antibodies in patients with mild, moderate, and severe COVID-19, analyzing their cross-reactivity with the Wuhan and Omicron variants. We also assessed the activation of the immune response by measuring serum cytokines in patients with mild, moderate, and severe COVID-19. Our findings suggest the early activation of neutralizing antibodies in moderate COVID-19 compared to mild cases. We also observed a strong correlation between the cross-reactivity of neutralizing antibodies to the Omicron and Wuhan variants and the severity of the disease. In addition, we found that Th1 lymphocyte activation was present in mild and moderate cases, while inflammasomes and Th17 lymphocytes were activated in severe COVID-19. In conclusion, our data indicate that the early activation of neutralizing antibodies is evident in moderate COVID-19, and there is a strong correlation between the cross-reactivity of neutralizing antibodies and the severity of the disease. Our findings suggest that the Th1 immune response may play a protective role, while inflammasome and Th17 activation may be involved in severe COVID-19.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	neutralizing antibodies	ru_RU
dc.subject	COVID-19	ru_RU
dc.subject	serum	ru_RU
dc.subject	Th1 lymphocyte	ru_RU
dc.title	Neutralizing Antibodies in COVID-19 Serum from Tatarstan, Russia	ru_RU
dc.type	Articles in international journals and collections	ru_RU